Onesource Specialty Pharma Limited
₹1,563.25-₹6.40 (-0.4%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹20,295 Cr
- P/E
- 76.8x
- EV / EBITDA
- -92.4x
- Revenue
- ₹1,300 Cr
- Net margin
- -226.7%
- ROCE
- -8.5%
Price chart
Technical chartScreen technicals →-15.5% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- +2.5%
- 3M
- -7.2%
- 6M
- -10.1%
- 1Y
- -15.5%
- 5Y
- -8.2%
52-week range
Day change -₹6.40 (-0.4%) from ₹1,570 to ₹1,563 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ONESOURCE, bought on each weekday since 2025.
AI Summary
Indian StockStrengths1
- Revenue grew 655.8% YoY
Concerns1
- Negative free cash flow (₹347 Cr)
Rule-based from financial data. Not advice.
About the company
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally.
Read moreShow less
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.
- Sector
- Healthcare
- Shares outstanding
- 11.4 Cr shares
- ISIN
- INE013P01021
- BSE code
- 544292
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹20,295 Cr
- P/E
- 76.8x
- P/B
- 3.4x
- EV / EBITDA
- -92.4x
- EV / Sales
- 120.9x
- P/S
- 118.0x
- Earnings yield
- 1.3%
- 52-week high
- ₹1,875.40
- 52-week low
- ₹1,111.10
Profitability
- Operating margin
- -47.7%
- Net margin
- -226.7%
- EBITDA margin
- -130.8%
- ROE
- -98.0%
- ROCE
- -8.5%
- ROA
- -27.3%
- Dividend payout
- 0.0%
- Tax rate
- 0.0%
- Other income, % of PBT
- 36.7%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,300 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 655.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹225 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 65.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -104.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹109 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -33.9%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹70.0 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -29.2%
Solvency and efficiency
- Current ratio
- 0.82
- Debt / Equity
- 1.43
- Debt / Assets
- 0.40
- Debt / EBITDA
- -2.54
- Financial leverage
- 3.58
- CFO / Net profit
- 0.28
- Cash / Market cap
- 1.7%
- Cash per share
- ₹31.12
- Asset turnover
- 0.12
- Fixed asset turnover
- 0.20
- Capital intensity
- 5.02
- Debtor days
- 118 days
- Inventory turnover
- 0.55
- Cash conversion cycle
- 363 days
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Sales | ₹1,300 Cr |
| Expenses | ₹930 Cr |
| Operating profit | ₹370 Cr |
| Other income | -₹95 Cr |
| Interest | ₹162 Cr |
| Depreciation | ₹135 Cr |
| Profit before tax | -₹22 Cr |
| Tax and other | -₹41 Cr |
| Net profit | ₹19 Cr |
Revenue and net profit
Revenue grew 655.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹21 Cr | -₹121 Cr |
| FY2022 | ₹132 Cr | -₹230 Cr |
| FY2023 | ₹39 Cr | -₹799 Cr |
| FY2024 | ₹172 Cr | -₹390 Cr |
| FY2025 | ₹1,300 Cr | ₹19 Cr |
Cash flows
FY2025: -₹47.0 Cr from operations, -₹347 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹115 Cr | -₹325 Cr |
| FY2022 | -₹420 Cr | -₹1,105 Cr |
| FY2023 | -₹165 Cr | -₹231 Cr |
| FY2024 | -₹109 Cr | ₹397 Cr |
| FY2025 | -₹47 Cr | -₹347 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,300 Cr+655.8%1Y
- Net profit
- ₹19 Cr
- Cash from operations
- -₹47 Cr
- Free cash flow
- -₹347 Cr-187.4%1Y
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,300 Cr | ₹370 Cr | — | ₹19 Cr | -₹47 Cr | -₹347 Cr | 0.3% | +655.8% | -104.9% |
Monthly returns
Month-by-month returns of ONESOURCE across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹7,497 Cr |
| Equity capital | ₹11 Cr |
| Reserves | ₹5,909 Cr |
| Borrowings | ₹942 Cr |
| Other liabilities | ₹635 Cr |
| Assets | ₹7,497 Cr |
| Fixed assets | ₹3,200 Cr |
| Capital work in progress | ₹206 Cr |
| Investments | ₹2,848 Cr |
| Other assets | ₹1,243 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ONESOURCE trades at 76.8x earnings against a peer median of 52.6x (a 46% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Onesource Specialty Pharma LimitedONESOURCEthis companyP/E ↑ premium | ₹20,295 Cr | 76.8x | 3.4x | -98.0% | -92.4x |
| Wockhardt LtdWOCKPHARMA | ₹22,539 Cr | 160.0x | 7.8x | -23.5% | -2690.8x |
| PIRAMAL PHARMA LIMITEDPPLPHARMA | ₹22,363 Cr | 31.7x | 2.9x | 5.8% | 27.6x |
| Pfizer Ltd.PFIZER | ₹22,230 Cr | 31.5x | 5.8x | 15.3% | 26.2x |
| AstraZeneca Pharma India Ltd.ASTRAZEN | ₹20,549 Cr | 88.9x | 25.7x | 22.8% | 86.6x |
| Eris Lifesciences LimitedERIS | ₹20,131 Cr | 71.4x | 7.3x | 11.9% | 45.5x |
| Sai Life Sciences LimitedSAILIFE | ₹19,113 Cr | 67.7x | 8.2x | 9.4% | 62.4x |
| Neuland Laboratories Limited.NEULANDLAB | ₹18,376 Cr | 94.3x | 11.4x | 23.5% | 38.6x |
| Ventive Hospitality LimitedVENTIVE | ₹17,846 Cr | 91.9x | 3.9x | 49.7% | 60.7x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
ONESOURCE since 1 January, against earlier years.
Historical volatility
ONESOURCE's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -337.0% |
| FY2022 | -72.0% |
| FY2023 | -303.0% |
| FY2024 | -48.0% |
| FY2025 | 28.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,300 Cr |
| Costs | |
| Interest | ₹162 Cr |
| Expenses | ₹930 Cr |
| Operating profitOperating Profit | ₹370 Cr |
| Other income and charges | |
| Profit before tax | -₹22 Cr |
| Tax | |
| Net profitNet Profit | ₹19 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹7,497 Cr |
| Equity capitalEquity Capital | ₹11 Cr |
| Reserves | ₹5,909 Cr |
| Borrowings | ₹942 Cr |
| Other liabilitiesOther Liabilities | ₹635 Cr |
| AssetsTotal Assets | ₹7,497 Cr |
| Fixed assetsFixed Assets | ₹3,200 Cr |
| Capital work in progressCWIP | ₹206 Cr |
| Investments | ₹2,848 Cr |
| Other assetsOther Assets | ₹1,243 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | -₹47 Cr |
| Investing cash flowCash from Investing Activity | -₹300 Cr |
| Financing cash flowCash from Financing Activity | ₹417 Cr |
| Change in cashNet Cash Flow | ₹70 Cr |
Learn while you research
Academy chapters picked for Onesource Specialty Pharma Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 76.8, learn when high multiples are justified.6 min read
- 04 Growth Investing656% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read